Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3824307 | 0.89 | MYC (0.67) | MYCALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL17744822 | 0.83 | MMP2 (0.57) | MYCALDH1A1HSD17B10KDM4EMMP2 | |
| SCHEMBL17744779 | 0.81 | MMP2 (0.55) | MYCALDH1A1HSD17B10KDM4EMMP2 | |
| SCHEMBL3278350 | 0.81 | MYC (0.56) | MYCALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL28597884 | 0.81 | MYC (0.46) | MYCALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL27998613 | 0.80 | CYP3A4 (0.50) | MYCALDH1A1CYP3A4TRPA1TDP1 | |
| SCHEMBL9271506 | 0.80 | MYC (0.44) | MYCALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL3825800 | 0.80 | MYC (0.59) | MYCALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL3716970 | 0.79 | MYC (0.61) | MYCALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL10527823 | 0.79 | MYC (0.57) | MYCALDH1A1HSD17B10KDM4EMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4711879-A | IMMUNO-MODULATING ACTIVITY | CIBA-GEIGY CORPORATION (US) | 1987-12-08 | — | — | US | claimed |
| US-4640911-A | IMMUNOSTIMULANTS, VIRICIDES SUCH AS HERPES SIMPLEX | CIBA-GEIGY CORPORATION (US) | 1987-02-03 | — | — | US | claimed |
| CN-115996715-A | Treatment of viral conjunctivitis | 奥可金公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-113164494-A | Agents and methods for modulating pathogen activity | 格里菲斯大学 | 2021-07-23 | — | — | CN | disclosed |
| US-9872846-B2 | High penetration compositions and uses thereof | TECHFIELDS PHARMA CO., LTD. (CN) | 2018-01-23 | — | — | US | disclosed |
| US-20170209585-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO LTD (CN) | 2017-07-27 | — | — | US | disclosed |
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | PREMIER RESEARCH INTERNATIONAL, LLC | 2017-07-27 | — | — | US | disclosed |
| US-20160175436-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | VICUS THERAPEUTICS LLC (US) | 2016-06-23 | — | — | US | disclosed |
| EP-3028743-A2 | COMPOSITIONS FOR MUCOSITIS AND ONCOLOGY THERAPIES | Vicus Therapeutics, LLC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20160129018-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | VICUS THERAPEUTICS LLC (US) | 2016-05-12 | — | — | US | disclosed |
| CN-102470120-A | Ophthalmic solutions for protecting the internal structure of the eyeball against ultraviolet rays or for treating keratoconus with a transepithelial cross-linking technique | SANSEVERINO RENATO | 2012-05-23 | — | — | CN | disclosed |
| US-20110158983-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | VICUS THERAPEUTICS, LLC | 2011-06-30 | — | — | US | disclosed |
| EP-2259844-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | Vicus Therapeutics SPE 1, LLC (US) | 2010-12-15 | — | — | EP | disclosed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | disclosed |
| WO-2009111648-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | VICUS THERAPEUTICS, LLC (US) | 2009-09-11 | — | — | WO | disclosed |
| US-4711879-A | IMMUNO-MODULATING ACTIVITY | CIBA-GEIGY CORPORATION (US) | 1987-12-08 | — | — | US | disclosed |
| US-4640911-A | IMMUNOSTIMULANTS, VIRICIDES SUCH AS HERPES SIMPLEX | CIBA-GEIGY CORPORATION (US) | 1987-02-03 | — | — | US | disclosed |
| US-4412996-A | ANTIINFLAMMATORY AGENTS | CRINOS FARMACOLOGICA SPA (IT) | 1983-11-01 | — | — | US | disclosed |
| EP-0050385-A1 | Piridoxine derivatives, a process for their preparation and related pharmaceutical compositions | D and D S.r.l. (IT) | 1982-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | MYC 4386/4885ALDH1A1 1790/4885HSD17B10 454/4885 |
| US-20170209585-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | MYC 4386/4885ALDH1A1 1790/4885HSD17B10 454/4885 |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | MYC 4386/4885ALDH1A1 1790/4885HSD17B10 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.